SUMM.L

Summit Therapeutics Plc
FTSE Russell - Summit Therapeutics
17th February 2020, 17:30
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 2596D
FTSE Russell
17 February 2020
 

 

 


 

 

Summit Therapeutics (UK): Constituent Deletion
Changes in FTSE UK Index Series

17 February 2020

Subject to the expected cancellation of trading on AIM for Summit Therapeutics (UK, constituent), please see details of affected indexes and effective dates below:

 

 

Index

Effective From
Start of Trading

FTSE AIM All-Share Index

24 February 2020

 

 

 

 

 

 

 

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia

+1800 653 680

Hong Kong

+852 2164 3333

Japan

+81 3 4563 6346

London

+44 (0) 20 7866 1810

New York

+1866 551 0617

                                   

 

Alternatively please visit our website at www.ftserussell.com

Terms of Use | Copyright © 2020 FTSE Russell

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FTSUBANRRNUUAAR ]]>
TwitterFacebookLinkedIn